In this study, we describe the effects produced by the retroviral transduction of human type I consensus IFN (CIFN) coding sequence into the 8863 and 1B6 human melanoma cell lines, derived from a metastatic and a primary human melanoma, respectively. Melanoma cell lines producing approximately 10 3 IU/ml of IFN were obtained. Interestingly, cisplatin treatment of IFN-producing 8863 and 1B6 melanoma cells resulted in a three-to four-fold increase in the percentage of apoptotic cells with respect to similarly treated parental or control-transduced cell cultures. A similar effect, although less intense, was caused by cultivation of parental melanoma cells in the presence of exogenous CIFN. The increased susceptibility of the IFN-producing melanoma cell lines to cisplatin-induced apoptosis was associated with an IFN-dependent accumulation of p53, which also correlated with a decrease in Bcl-2 expression. Addition of exogenous CIFN to parental melanoma cells resulted in similar although weaker modulations of p53 and Bcl-2 expression. Cisplatin administration to nude mice bearing 3-day-old IFN-producing 8863 tumors resulted in complete tumor regression, while only a partial tumor inhibition was observed upon cisplatin treatment of mice bearing parental or control-transduced 8863 tumors. Starting the cisplatin treatment 7 days
Introduction
The identification of effective therapeutic strategies for the treatment of high-risk and malignant melanoma represents a challenge for biomedical research, in spite of the progress achieved as a result of intensive clinical work. 1 IFN-␣ is currently used in the therapy of melanoma and is the only treatment that has been shown to increase disease-free and overall survival in patients with high-risk melanomas. 2 Encouraging results have been obtained in clinical trials combining chemotherapy and immunother-after tumor cell injection still resulted in a stronger inhibition of tumor growth in the mice bearing IFN-producing 8863 tumors as compared with parental tumor-bearing mice. A comparable therapeutic effect was obtained after repeated peritumoral administration of 10 3 IU of exogenous CIFN and cisplatin treatment. Interestingly, a spontaneous tumor regression was observed in nude mice injected with IFNproducing 1B6 cells, in contrast to the progressive tumor growth occurring in mice receiving a similar inoculum of the parental or control-transduced 1B6 melanoma cells. Repeated peritumoral administration of 10 3 IU of exogenous CIFN to mice bearing parental 1B6 tumors caused only a transient inhibition of tumor growth. These results indicate that type I IFN gene transfer is an effective approach for suppressing the tumorigenic phenotype of human melanoma cells and for increasing the efficacy of anticancer drugs. These observations, together with our previous findings showing the importance of IFN-␣-T cell interactions in the generation of an antitumor response in mouse models, underline the interest of using type I IFN in gene therapy strategies for the treatment of human melanoma. Gene Therapy (2000) 7, 167-179.
apy, in particular IFN-␣ and IL-2, for the treatment of patients with metastatic malignant melanoma. 1 However, further investigation is needed for the identification of the optimal dose and scheduling of IFN-␣ as a single agent or in combination therapies in order to optimize the efficacy and minimize the toxicity of this cytokine. 3 In fact, because of the notable side-effects often associated with the conventional use of IFN-␣, studies aimed at the definition of novel therapeutic interventions with this cytokine are strongly encouraged. 3 Cytokine gene transfer into tumor cells has recently received particular attention as a potentially useful approach for the cancer therapy, and several clinical trials have been started using cytokine gene-modified tumor cells. 4 Although IFN-␣ is the first cytokine to be used clinically in the treatment of cancer patients and has been Gene Therapy shown to be therapeutically effective against some human malignancies, 5 its use in cytokine gene therapy of human cancer has not been considered to date. This is particularly surprising when considering the pleiotropic biologic activities exhibited by this cytokine. In fact, type I IFNs exert direct effects on tumor cells, such as the down-regulation of oncogene expression and induction of tumor suppressor genes, which can contribute to the antiproliferative activity of these cytokines, and the increase of MHC class I expression, which can enhance immune recognition. 5, 6 Moreover, type I IFNs also have important immunoregulatory functions, promoting macrophage differentiation, increasing NK cells and CD8
+ CTL cytotoxicity, and favoring the differentiation of type 1 T helper cells (reviewed in Ref. 6) .
Recent studies have shown that IFN-␣ gene transfer into different mouse metastatic tumor cell lines resulted in a marked loss of tumorigenicity. [7] [8] [9] [10] [11] [12] Rejection of the IFN-␣-producing tumor cells consistently led to the development of long-lasting tumor-specific immunity which, in some cases, was clearly mediated by CD8 + T lymphocytes. 8 Notably, in a recent study in which we specifically selected a highly metastatic mouse tumor resistant to therapy with large doses of IFN-␣/␤, we found that the genetically modified tumor cells expressing IFN-␣ were efficiently rejected by host-mediated mechanisms when injected into immunocompetent syngeneic mice, suggesting that there might be some advantages in transducing this cytokine gene with respect to the conventional therapy. 13 IFN-␣ gene therapy using gene-modified tumor cells or fibroblasts as well as viral vectors has been shown to suppress effectively the growth of mouse 7, 12 or human tumors implanted into nude mice. [14] [15] [16] [17] In some of these studies, a better therapeutic effect was achieved when the treatment of tumorbearing mice with IFN-␣-expressing cells was combined with chemo-or chemoimmunotherapy. 15, 16 In particular, we have recently shown that combined therapy with tumor cells expressing both IFN-␣ and the autotoxic herpes simplex thymidine kinase gene resulted in the cure of the majority of mice bearing established parental tumors, following treatment with the prodrug ganciclovir. 18, 19 Accordingly, it was of interest to evaluate the effects of the genetic modification of human melanoma cell lines with retroviral vectors carrying the type I consensus IFN (CIFN) coding sequence. In this study, we characterized IFN-producing cell lines obtained after retroviral transduction of a metastatic or a primary human melanoma. We show that the constitutive expression of type I IFN into these melanoma cell lines resulted in strong augmentation of sensitivity to cisplatin-induced apoptosis, which correlates with an IFN-dependent accumulation of p53 protein. Overall, these results suggest a potential advantage of therapeutic strategies based on the use of IFN-␣-producing melanoma cells or on the in vivo transduction of melanoma tumors with IFN-␣.
Results
Isolation and in vitro characterization of IFN-producing human melanoma cell lines The human melanoma cell lines 8863 (metastatic melanoma) 20 and 1B6 (primary melanoma) 21 were infected with the recombinant retroviruses LXSN and LCIFNSN, derived from the retroviral vectors schematically depicted in Figure 1 . Following selection into G418-containing medium, cell lines producing approximately 1000 IU/ml of IFN were isolated from both 8863 and 1B6 cells (Table 1) . No biologically active IFN was detected in the culture supernatant of either parental or control-transduced 8863-LXSN and 1B6-LXSN cell lines. These cell lines were used in all the subsequent experiments as controls of possible effects of vector sequences. The analysis of the in vitro growth characteristics showed greater proliferation ability of the parental 8863 cells as compared with the parental 1B6 cells, as indicated by the higher cell number reached at confluency (Figure 2 ). The proliferation ability of the IFN-producing 8863 cells was inferior to that of the parental and control counterparts, showing a significant decrease in the total number of cells achieved at confluency (Figure 2 ). In contrast, no differences were observed in the in vitro growth properties of the IFN-producing versus the parental 1B6 cells (Figure 2 ).
Activated IFN-induced responses in genetically modified melanoma cells producing CIFN In order to assess whether the constitutive IFN production had caused the selection of IFN-resistant cells, we tested the susceptibility of the different cell lines to the infection with vesicular stomatitis virus (VSV). Treatment of parental 8863 and 1B6 cells with 100 IU/ml of exogenous CIFN caused approximately a 10-fold and a 100-fold reduction, respectively, of the titers of virus produced after infection with VSV as compared with the untreated parental and control-transduced counterparts ( Table 2) . The results showed a sensitivity of both melanoma cell lines to the antiviral activity of CIFN, which was greater in the case of 1B6 cells. Accordingly, the VSV yields obtained after infection of IFN-producing 8863 and 1B6 cells were 100-fold and 10 000-fold lower, respectively, than those observed in the parental and control counterparts ( Table 2) . Treatment of the 1B6 cells with a dose of exogenous CIFN comparable to the amount of the cytokine secreted by the 1B6-IFN cells resulted in a similar inhibition of VSV production ( Table 2 ). These results indicate that the phenotype and the degree of sensitivity to the antiviral activity of CIFN exhibited by the parental melanoma cells had been maintained in both melanoma cell lines following the transduction and selection processes and in spite of the constitutive secretion of the cytokine. Further evidence that IFN-induced responses were activated in the IFN-producing melanoma cell lines came from the Western blotting analysis Gene Therapy of the expression levels of the STAT-1 and IRF-1 proteins, whose increase is considered as a consequence of IFNactivated signaling pathways. 22 Higher levels of STAT1 and IRF-1 proteins were constitutively induced in both 8863-IFN and 1B6-IFN cells as compared with the basal level of expression observed in the parental and controltransduced counterparts (Figure 3) . A comparable increase of the STAT1 and IRF-1 proteins was observed following cultivation of the parental 8863 and 1B6 in the presence of exogenous CIFN (Figure 3 ).
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Cisplatin-induced apoptosis in parental and genetically modified melanoma cells We next evaluated the in vitro sensitivity to cisplatin of the IFN-producing versus their parental or control counterparts. Evaluation of the percentage of apoptotic cells, after staining with Hoechst 33258, indicated that the parental 1B6 cells were more sensitive to the drug as compared with the parental 8863 cells. In fact, approximately 20% of 8863 cells underwent apoptosis after 48 h of treatment with a suboptimal dose of cisplatin (50 m) ( Figure 4A) . A similar percentage of apoptotic cells was found already at 24 h after the addition of cisplatin to the 1B6 cell line ( Figure 4A ), and 40% of 1B6 cells were IFN-dependent modulation of the expression of p53 in genetically modified melanoma cell lines and effect of cisplatin treatment We then quantitatively evaluated whether the expression of some proteins involved in the apoptotic process could be modulated by IFN, either exogenously administered or constitutively produced, in the absence or in the presence of cisplatin treatment. In particular, we analyzed by flow cytometry the expression levels of p53, p21 WAF1/CIP1 , Bcl-2, Bcl-X L , Bax, iNOS, Fas and FasL. An increase of Bax and Fas and a decrease of Bcl-X L was observed in all the different cell lines after cisplatin addition, independently of IFN (data not shown). The expression of FasL was not modulated by either IFN or cisplatin (data not shown). In contrast, as shown in Figure 5 , the constitutive production of IFN caused a significant increase of the expression levels of p53 in both 8863 and 1B6 cells at 48 h after seeding as compared with the control 8863-LXSN and 1B6-LXSN cells (panels b and h). Interestingly, in the IFN-producing 1B6 cell line two distinct cell populations expressing higher levels of p53 could be distinguished, with the more strongly positive cell fraction exhibiting amounts of p53 comparable with those found in the IFNproducing 8863 cells. Treatment of parental 8863 and 1B6 cells with exogenous CIFN resulted in a slight increase in p53 expression as compared with the untreated parental cells (panels a and g). However, this effect, more evident in the 1B6 cell line (panel g), was much less intense than that caused by the constitutive production of the cytokine in both 1B6 and 8863 cell lines (panel a versus b, and g versus h). Cisplatin treatment did not substantially modulate p53 expression in the parental 8863 cells, cultivated or not in the presence of IFN, with respect to the expression levels found before cisplatin treatment (panel c and e versus a). In contrast, a stronger increase in the expression of p53 was observed 48 h after cisplatin addition in the IFN-producing 8863 cells as compared with the control 8863-LXSN cells (panel f versus d and b). Differently to what was observed for the 8863 cell line, higher levels of p53 were already detected in the parental 1B6 cells after 24 h of cisplatin treatment (panel i versus g). Whereas cultivation of these cells in the presGene Therapy ence of exogenous CIFN did not affect the cisplatininduced increase of p53 at 24 h after cisplatin addition, it resulted in a further augmentation of p53 expression after 48 h of cisplatin treatment, which did not occur in the parental 1B6 in the absence of the cytokine (panel k versus i). The IFN-mediated potentiation of cisplatin-induced p53 expression was confirmed in the IFN-producing 1B6 cells as compared with the control 1B6-LXSN cells (panel j and l versus h). Notably, this effect was much more pronounced as compared with that produced by the exogenous cytokine, similarly to what was observed for the IFNproducing 8863 cells. Interestingly, after cisplatin addition, a decrease in the amount of Bcl-2 protein was detected in IFN-producing 8863 as well as in both the IFN-producing 1B6 cells and in the parental 1B6 cells cultivated in the presence of exogenous CIFN (Table 3) . Notably, only after 48 h of drug treatment did the IFNproducing 8863 cells exhibit significantly lower levels of Bcl-2 with respect to the parental, IFN-treated and control LXSN counterparts. In contrast, a significant decrease in Bcl-2 expression was detected already at 24 h after cisplatin addition in the IFN-treated and IFN-producing 1B6 cells as compared with parental and control cells, followed by a further decrease at 48 h (Table 3 ).
An increase in the expression levels of iNOS and p21 WAF1/CIP1 was caused by cisplatin treatment in all the different cell lines (Table 3 ). Significant differences in the amount of iNOS were found in the IFN-producing 1B6 cells with respect to the control 1B6-LXSN cells after 24 h of treatment (Table 3 ). Higher p21 WAF1/CIP1 levels were observed in IFN-treated and IFN-producing 1B6 cells as compared with parental and control counterparts, respectively, at 48 h after drug addition, whereas no differential modulation of this protein was induced by CIFN in cisplatin-treated 8863 cells (Table 3) .
In vivo efficacy of cisplatin administration to nude mice bearing established parental or IFN-producing melanoma tumors Based on our observation of a higher apoptotic response to cisplatin in IFN-producing melanoma cells, we then asked whether IFN-producing melanoma tumors established into nude mice exhibited a differential response to cisplatin administration with respect to parental or control-transduced tumors. In preliminary experiments, aimed at the characterization of the tumorigenic properties of the different melanoma cell lines, we observed that the tumorigenic behavior of 8863 and 1B6 cells was differently affected by the constitutive production of CIFN. In fact, the subcutaneous (s.c.) inoculation of 2 × 10 6 IFNproducing 8863 cells resulted in a progressive tumor growth comparable with that observed in nude mice receiving a similar inoculum of parental or control-transduced 8863 cells (Figure 6a ). In contrast, the s.c. injection of 2 × 10 6 IFN-producing 1B6 cells resulted in an initial tumor take, which was followed by a complete tumor regression in the totality of the injected mice, whereas a similar injection of parental or control-transduced 1B6 cells gave rise to progressively growing tumors (Figure 6b ). The gross examination of the tumor area in mice killed at different times after the injection of 1B6-IFN cells suggested that tumor regression in these mice was associated with a strong inhibition of tumor-induced angiogenesis (unpublished observations). Interestingly, the repeated peritumoral treatment of nude mice bearing We also tested the efficacy of cisplatin treatment in nude mice injected with 8863-derived cell lines. Prelimi- nary experiments aimed at definition of the optimal treatment schedule indicated that the best therapeutic response was obtained following repeated weekly injections of cisplatin (5 mg/kg) at the site of parental 8863 tumor growth. Administration of the same dosage of cisplatin by the intraperitoneal route resulted in significant toxicity and lowering the dose of cisplatin or the number of injections did not significantly reduce tumor growth (data not shown). Therefore, we comparatively evaluated the effects of repeated peritumoral injections of cisplatin in nude mice previously injected with parental or controlGene Therapy Table 4 , indicated that cisplatin administration to nude mice bearing 3-day-old IFN-producing 8863 tumors resulted in complete tumor eradication in all the injected mice. In contrast, the mice bearing parental or control- transduced 8863 tumors experienced, after similar cisplatin treatment, only a transient reduction of tumor burden (Table 4) , which was followed by regrowth of the tumor. When the cisplatin administration was delayed to day 7 after tumor cell injection, a lower percentage of tumor regression was observed in the mice bearing IFN-producing 8863 tumors (Table 5) . However, the size of the IFNproducing 8863 tumors was greatly reduced by cisplatin treatment, whereas the growth of the parental 8863 tumors was not significantly affected by cisplatin administration (Table 5) . Interestingly, repeated peritumoral injections of CIFN (1000 IU per mouse) were necessary to obtain, after cisplatin administration, a degree of tumor reduction and eradication comparable with that caused by cisplatin in the mice bearing IFN-producing tumors (Table 5) .
Discussion
This study describes the effects exerted by the transfer of the human type I consensus IFN (CIFN) gene into two different human melanoma cell lines. The most striking results concern the IFN-mediated potentiation of cisplatin cytotoxicity via induction of apoptosis and the molecular mechanisms associated with this effect. In fact, treatment of both IFN-producing 8863 and 1B6 cells with a sub- a Six-week-old Swiss nude mice were injected s.c. with 2 × 10 6 cells of the indicated cell lines. Seven days after tumor cell injection, cisplatin (5 mg/kg) was administered peritumorally once a week for 3 weeks. b The indicated amounts of CIFN were administered peritumorally every 2 days for a total of nine injections. c The values refer to day 62 after tumor cell injection. NS, not significant. optimal dose of cisplatin caused a much stronger apoptotic response than that observed in similarly treated parental and control-transduced counterparts (Figure 4 ). The addition of exogenous CIFN to parental 8863 and 1B6 cell cultures also resulted in a more potent induction of apoptosis following cisplatin addition as compared with parental cells cultivated in the absence of the cytokine (Figure 4) . Interestingly, however, the augmentation of cisplatin cytotoxicity caused by amounts of IFN comparable with those secreted by the IFN-producing cells was in all cases less intense as compared with that induced by the constitutively produced cytokine (Figure 4 . 23) . The sensitivity to anticancer drugs has been reported to be p53 dependent for several human tumors and the introduction of wild-type p53 into tumor cells has been reported to sensitize a variety of cancer cell lines to different anticancer drugs, including cisplatin, in vitro and in vivo. 23 However, other studies have indicated that wildtype p53 protects from anticancer drug-induced apoptosis. 23 With regard to melanoma tumors, a recent report showed that four different melanoma cell lines containing a wild-type p53 gene exhibited a much higher apoptotic response to different chemotherapeutic agents, including cisplatin, as compared with four melanoma cell lines carrying the mutant p53. 24 These results are in contrast with a previous study showing that overexpression of wild-type p53 was associated with cell cycle arrest and cisplatin resistance in a human melanoma cell line. 25 Treatment of this cell line with IFN-␣ inhibited p53 expression and increased sensitivity to cisplatin, apparently releasing the cells from a quiescent state. 25 The results reported in our study show that an increased apoptotic response to cisplatin treatment is associated with a IFN-mediated accumulation of p53. It is possible that in our 8863 and 1B6 cell lines the augmentation of p53 cannot promote cell cycle arrest. Various studies suggest that apoptosis often occurs in the presence of p53 when cells fail to arrest in G 1 phase. 26 The observations that low basal levels of p21 WAF1/CIP1 were expressed by the 8863 and 1B6 cells, and that cisplatin treatment did not result in an increase of this protein comparable with that observed for p53, may reflect a relative inability of the melanoma cell lines utilized in our study to activate the growth arrest pathway, which is generally mediated by p53-induced p21 WAF1/CIP1 . 26 In this context, the DNA damage caused to the 8863 and 1B6 cells by cisplatin treatment would preferentially lead to p53-mediated apoptosis. The decrease in Bcl-2 protein levels which followed cisplatin treatment of 8863 and 1B6 cells (Table 3) further supports this concept, as Bcl-2 inhibits apoptosis in many systems in response to a variety of apoptotic stimuli, including chemotherapeutic drugs and its expression has been shown to be down-regulated by p53. 23, 27 The most intriguing difference between the results reported by Davol and colleagues 25 and our study regards the opposite effects exerted by IFN-␣ on the levels of p53 expression. Although the explanation for such a difference is at present unknown, it is striking that in both cases the IFN-mediated modulation of p53 correlates with an increased sensitivity to cisplatin, suggesting that, depending on the cellular context, IFN-␣ can differentially target growth regulatory pathways in order to restore or augment the response to anticancer drugs. In this regard, it should be noted that a synergistic effect of IFN-␣ in combination with chemotherapeutic agents has Gene Therapy been reported both in clinical trials and experimental studies. 28, 29 Consistently, we show that cisplatin treatment of nude mice bearing 3-day-old IFN-producing 8863 tumors resulted in the cure of all the injected mice, whereas it caused only a delay in tumor progression in the mice injected with the parental or control-transduced 8863 cells (Table 4) . Cisplatin administration to nude mice bearing more advanced (7-day) tumors also resulted in a higher inhibition of tumor growth in the group of mice injected with the IFN-producing 8863 cells as compared with mice bearing parental tumors (Table 5) . These results strongly suggest that the antitumor efficacy of in vivo cisplatin administration is more potent when associated with a local release of constant amounts of IFN by the melanoma cells. This concept is further supported by the observation that repeated peritumoral administration of 1000 U of CIFN was necessary in order to achieve a therapeutic effect of cisplatin comparable with that observed in the mice bearing IFN-producing tumors (Table 5 ). The amount of local IFN rendered available by the repeated injections of the exogenous cytokine likely exceeds that present in the microenvironment of IFN-producing tumors after cisplatin treatment. In fact, the in vivo killing of tumor cells caused by cisplatin leads to a progressive decrease in the number of IFN-producing tumor cells and, as a consequence, to a diminished in vivo release of IFN, whereas in the mice receiving exogenous CIFN the cytokine is continuously replenished during cisplatin treatment.
The potential of the constitutive IFN production in modulating the tumorigenic behavior of melanoma cells is strongly suggested by the observation that the tumors formed after injection of IFN-producing 1B6 cells into nude mice underwent spontaneous regression (Figure 6 ), which could not be obtained by repeatedly administering exogenous CIFN to mice bearing parental 1B6 tumors ( Figure 7) . Interestingly, the CIFN gene transfer into 8863 melanoma cells did not result in any modification of the tumorigenic characteristics ( Figure 6 ). As the 1B6 cells derive from a primary melanoma and the 8863 cell line was established from a metastatic melanoma, our observations might suggest a higher sensitivity of primary melanomas to the antitumor effects produced by IFN-␣ gene transfer. However, a comparison of the effects of this cytokine, given exogenously versus genetically transferred, on a larger panel of primary versus metastatic melanoma cells is needed in order to investigate this aspect better, that may have important clinical relevance.
IFN-induced pathways appear to be necessary for sensitizing to apoptosis-inducing stimuli, as indicated by the observation that the deletion of the IRF-1, protein kinase R, or RNase L genes results in the resistance to apoptosis induced by different stimuli. 30, 31 Although our results strongly suggest that the IFN-mediated potentiation of cisplatin-induced apoptosis of melanoma cells is, at least in part, dependent upon an accumulation of p53 protein, we cannot rule out other possible mechanisms. In particular, the higher expression of IFN-inducible proteins such as IRF-1 and STAT1 in the IFN-treated and IFNproducing melanoma cells (Figure 3 ) may be responsible not only for the induction of an antiviral state (Table 2) in the target cells, but also for the activation of pathways directly involved in the apoptotic process. In fact, both IRF-1 and STAT1 have been shown to favor the induction of apoptosis by different stimuli, apparently by reg-ulating the expression of different members of the family of caspases responsible for the final steps of apoptosis execution. [32] [33] [34] Interestingly, induction of apoptosis following overexpression of p53 was found to be associated with activation of ICE-like proteases. 35 Ongoing studies will clarify whether the IFN-mediated enhancement of cisplatin sensitivity in the 8863 and 1B6 melanoma cells is dependent on an increase of caspase activity.
Evidence indicates that type I IFN plays a crucial role in the activation of a protective antitumor T cell-mediated immune response (reviewed in Ref. 36) . Recently, type I IFN has been shown to promote the in vivo proliferation and long-term survival of antigen-specific CD8 + T cells in mouse models, 37, 38 and to favor a Th-1 type of immune response 39, 40 as well as the differentiation and functional activation of dendritic cells in human systems. [41] [42] [43] Thus, the emerging scenario is that IFN-␣ may have some unique properties of acting as tumor suppressor gene and T cell adjuvant. With specific regard to our study, it is of interest to mention that recent reports have shown that CTLs which specifically recognize a wild-type p53 epitope efficiently lysed human breast carcinoma and melanoma cells which accumulated the p53 protein, 44 and significantly reduced the growth of human tumor xenografts in SCID mice. 45 Therefore, it will be of interest in future studies to evaluate whether the accumulation of p53 protein, together with the increase of HLA class I antigens and the restoration of B7.1 costimulatory molecule expression observed in the IFN-producing 8863 and 1B6 melanoma cells (unpublished observations), confer to these cells a greater immunogenicity as compared with the parental counterparts.
Although IFN-␣ as a single agent has shown a clear therapeutic benefit in patients with high-risk melanomas 2 and combination of IFN-␣ with chemotherapy appears to hold promise for the treatment of malignant melanoma, 1 treatment with this cytokine is associated with considerable toxicity. The results presented in our study indicate that type I IFN augments the sensitivity of melanoma cell lines to cisplatin both in vitro and in vivo, modulates the expression of molecules involved in the apoptotic process, and in some cases, inhibits the growth of melanoma tumors in nude mice. These effects appear particularly intense in tumor cells genetically modified for the production of IFN, suggesting that therapeutic strategies based on the use of IFN-␣-producing melanoma cells or on the in vivo transduction of melanoma tumors with IFN-␣ genes may offer potential advantages over the use of the exogenous cytokine in terms of reduced toxicity and increased efficacy.
Materials and methods

Cell lines
The HLA-A2 1B6 and 8863 melanoma cell lines were previously obtained from two patients' fresh tissues. 20, 21 The 1B6 clone was isolated from the Me10538 cell line, established from a primary skin melanoma lesion, 21 whereas the 8863 cell line was derived from a metastatic melanoma. 20 The HLA haplotype of the two patients, previously identified, was: patient 10538: HLA-A2, -A28, -B27, -B45, -C-, -C-, -DR7; patient 8863: HLA-A2, -A1, -B8, -B35, -Cw4, -C-, -DR3, -DR11. 20 The 1B6 and 8863 cell lines had been previously shown not to express the B7.1 co-stimulatory molecule. 20 Both cell lines were cultivated in RPMI-1640 supplemented with 50 u/ml penicillin, 50 g/ml streptomycin (BioWhittaker, Verviers, Belgium), and 10% FCS (Sebam, Berlin, Germany).
Mice
Male nude Swiss mice, 6-7 weeks old, were obtained from Charles River Breeding Laboratories (Italia Calco, Italy).
Recombinant retrovirus production and infection of melanoma cells
The LXSN retroviral vector, 46 containing the neomycin resistance gene under the control of the SV40 promoter, was obtained from AD Miller (Fred Hutchinson Cancer Research Center, Seattle, WA, USA). The LCIFNSN retroviral vector was constructed by cloning of the EcoRIBamHI fragment of plasmid pIFNSS 47 into the LXSN vector. The pIFNSS construct, kindly provided by Amgen (Thousand Oaks, CA, USA), contains a sequence encoding a signal peptide, corresponding to that most commonly found in human IFN-␣ subtypes, followed by the sequence encoding CIFN, a synthetic IFN whose amino acid residues are common to naturally occurring human IFN-␣ subtypes. 47 Both LXSN and LCIFNSN recombinant retroviruses were obtained following standard transinfection procedures in GP+E86 48 and GP+envAm12 49 packaging cells. The supernatants of individual clones of transduced GP+envAm12 cells, isolated by selection into G418-containing medium, were assayed for IFN and retrovirus production. The supernatants of the clones of transduced GP+envAm12 packaging cells exhibiting the highest titer (expressed in colony-forming units (CFU)/ml) of LXSN and LCIFNSN retroviruses were utilized for infection of 1B6 and 8863 melanoma cells. Briefly, 5 x 10 5 exponentially growing melanoma cells were centrifuged, after trypsinization, resuspended in 1 ml of virus-containing supernatants at a multiplicity of infection of 1 CFU per cell in the presence of 8 g/ml of polybrene, and incubated at 37°C in 5% CO 2 atmosphere for 2 h. After incubation, 1 ml of medium was added to the cultures, which were incubated at 37°C in 5% CO 2 atmosphere for 16 h. The infected cells were then selected in medium containing 800 g/ml of G418 (calculated to give 100% antibiotic activity, Geneticin; GibcoBRL, Grand Island, NY, USA), expanded into cell lines, and subjected to further analysis.
IFN titration
IFN was titrated on HeLa cells as described elsewhere. 17 IFN titers are expressed as IU. Human recombinant CIFN had a specific activity of 1 × 10 9 units/mg protein and was kindly provided by Amgen.
Assay of sensitivity of parental or transduced melanoma cell lines to the antiviral effect of CIFN The transduced cell lines were seeded at 2 × 10 5 cells in 35 mm diameter Petri dishes in duplicate. The parental cell lines were seeded at the same cell density, in duplicate, in the absence or in the presence of the indicated amounts of exogenous CIFN. After 24 h, the medium was removed from the cultures and the cells were infected with a suspension containing vesicular stomatitis virus (VSV) in Dulbecco 2% FCS at a multiplicity of infection of 2.5 plaque forming units (p.f.u.) per cell. After 1 h adsorption at 37°C in 5% CO 2 atmosphere, the cultures were washed and refed with fresh Dulbecco 2% FCS fresh medium. Twelve to 15 h later, the culture medium was collected, filtered through 0.45 m pore filters, and serial 10-fold dilutions were prepared. A quadruplicate of 2 × 10 4 monolayered HeLa cell cultures was infected with each dilution. Serial 10-fold dilutions of a control VSV preparation were used as a control for viral replication. The infected cultures were incubated at 37°C in 5% CO 2 atmosphere, and the cytopathic effect was evaluated at 24 and 48 h after infection by light microscopy examination. The titer of VSV yield was calculated by Karber method and expressed in TCID 50 /ml.
Western blotting analysis
Whole cell extracts were prepared by suspending the cell pellets in lysis buffer (10 6 cells/50 l) containing 50 mm Tris-HCl pH 7.5, 2 mm EDTA, 100 mm NaCl, 1 mm Na 3 Vo 4 , 1% NP40, 10 g/ml leupeptin, 5 g/ml aprotinin, 10 g/ml PMSF. After incubation at 4°C for 30 min, the lysates were centrifuged at 4°C for 15 min, and the protein content of the supernatant was determined by Bio-Rad protein assay (Bio-Rad Laboratories, Munich, Germany). For each sample, 25 g of protein extract were solubilized by boiling in SDS sample buffer with reducing agents and applied to 8% or 10% SDS-polyacrylamide gels, together with prestained molecular weight markers (Amersham). The proteins were then electrophoretically transferred to PVDF membrane filters (BioRad, Hercules, CA, USA). Blotted membranes were blocked with 5% dried milk in Tris-buffered saline for 2 h at room temperature, and incubated for 1 h in the same blocking solution containing specific antibodies to IRF-1 (rabbit polyclonal anti-human IRF-1 C-20 antibody; Santa Cruz Biotechnology, Santa Cruz, CA, USA), STAT1 (mouse monoclonal anti-human STAT1 antibody; Transduction Laboratories, Lexington, KY, USA), or ␤-tubulin (monoclonal anti-human ␤-tubulin, clone TUB 2.1; Amersham, Arlington Heights, IL, USA). After incubation, the filters were extensively washed in Tris-buffered saline containing 0.1% Tween 20 and incubated with secondary horseradish peroxidase-linked anti-rabbit or anti-mouse Ig antibodies (Amersham). Band detection was carried out by using the enhanced chemiluminescence system (ECL; Amersham). In some cases, the antibodies were stripped by incubating the nitrocellulose membranes for 30 min at 50°C in 62 mm Tris-HCl pH 6.8, 2% SDS, 100 mm ␤-mercaptoethanol, followed by extensive washing with Tris-buffered saline containing 0.1% Tween 20. The filters were then blocked again, reacted with the appropriate antibody, and treated as described above.
Fluorescence microscopy evaluation of apoptosis induced by cisplatin treatment in the parental and transduced melanoma cell lines Parental melanoma cells, cultivated in the absence or in the presence of 1000 IU/ml of CIFN, or transduced melanoma cells were grown on 13 mm diameter glass coverslips in separate wells (5 × 10 4 cells per well) in 24-well plates. After 48 h incubation at 37°C in 5% CO 2 atmosphere, medium was removed and the cells were exposed for 1 h to fresh medium in the absence or in the presence of increasing concentrations of cisplatin (0-200 m), washed, and cultivated in fresh culture medium for up to 48 h. Twenty-four and 48 h after treatment, both
Gene Therapy control and cisplatin-treated cells were fixed for 10 min at room temperature with 3.7% formaldehyde in PBS containing 2% bovine serum albumin (BSA). After washing in the same buffer, the cells were permeabilized for 10 min at room temperature with 0.5% Triton X-100. To evaluate the percentage of apoptosis, the cells were stained with the chromatin dye Hoechst 33258 (Molecular Probes, Eugene, OR, USA). Quantitative evaluation of apoptotic cell death was performed by counting at least 500 cells at high magnification (500×) in triplicate samples for each point as previously described. 50 The numbers reported represent the mean values ± standard deviation (s.d.) obtained in three separate experiments. In some experiments, the percentage of apoptotic cells was determined after resuspension of 10 6 cells in 1 ml of a solution containing 0.1% Na-citrate, 0.1% Triton X-100, 100 U of RNAse, and 50 g of propidium iodide. Following incubation at 4°C for 1 h, stained cells were analyzed with a FACScan cytometer (Becton Dickinson, San José, CA, USA) using Lysis II software (Becton Dickinson). The relative fluorescence intensity per cell was evaluated from samples of 1000 cells each.
Flow cytometry
Specific monoclonal antibodies (MAbs) were used for detection of inducible nitric oxide synthetase (mouse anti-human iNOS; Transduction Laboratories), p53 (mouse anti-human p53; Chemicon International, Temecule, CA, USA), Bcl-2 (100) (Santa Cruz), p21 WAF1/CIP1 (Ab-2, mouse anti-human clone DCS-65; NeoMarkers, Fremont, CA, USA), Fas (mouse anti-human CD95; Chemicon), and FasL (mouse anti-human Fas ligand, clone NOK-1; Pharmingen, San Diego, CA, USA). For detection of Bax and Bcl-X L , the cells were stained with specific rabbit polyclonal antibodies (PAbs) (Santa Cruz). Cisplatin-and control-treated cells were pelleted, fixed in 70% ice-cold methanol, and washed twice with cold PBS. The cells were then incubated for 30 min at 4°C with specific antibodies, washed twice and incubated for 30 min at 37°C with FITC-labeled anti-mouse (MAbs) or anti-rabbit (PAbs) (Sigma, St Louis, MO, USA). After washing, stained cells were analyzed with a FACScan cytometer (Becton Dickinson) using Lysis II software (Becton Dickinson). The relative fluorescence intensity per cell was evaluated from samples of 10 000 cells each.
Statistical analyses
The statistical significance of the differences observed in the percentage of apoptotic cells following cisplatin treatment was calculated by means of the Student's t test for correlated samples. A P Ͻ 0.01 was considered significant. Concerning the flow cytometry analyses, the statistical significance of the differences observed was calculated by using the Kolmogorov-Smirnov (K/S) test included in Lysis II software (Becton Dickinson).
